Yasuo Kohashi

Publications (3)2.83 Total impact

• Article: A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.

  Yoshitaka Totani, Yuji Saito, Masamichi Hayashi, Toshihiko Tada, Yasuo Kohashi, Yuki Mieno, Atsushi Kato, Hiromi Imizu, Yukiko Yoneda, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Mitsushi Okazawa, Hiroki Sakakibara
  [show abstract] [hide abstract]
  ABSTRACT: To assess the efficacy and toxicity of an oral anticancer fluoropyrimidine derivative, S-1, for previously treated patients with advanced non-small cell lung cancer (NSCLC). Patients with advanced (clinical stage IIIB-IV) NSCLC who had previously received one platinum-based chemotherapy were enrolled. S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b.i.d. for 28 consecutive days, repeated every 6 weeks. Between August 2005 and July 2007, 50 patients were entered into this study. Six patients achieved partial response (PR), and the overall response rate of eligible patients was 12.5% (6/48) (95% confidence interval (95%CI), 3.1-21.9%). Disease control rate was 39.6% (19/48) (95%CI, 25.7-53.4%). Median progression-free survival was 2.5 months. Median survival time was 8.2 months, and 1-year survival rate was 29.6%. No grade 4 toxicities were encountered. Grade 3 hematological toxicities comprised neutropenia in one patient (2.1%) and anemia in one patient (2.1%). Grade 3 non-hematological toxicities were observed in only five patients (10.4%). Treatment-related death did not occur. S-1 is an active and well-tolerated monotherapy for second-line treatment of advanced NSCLC.
  Cancer Chemotherapy and Pharmacology 05/2009; 64(6):1181-5. · 2.83 Impact Factor
• Article: [The relationships between initial clinical features and prognosis in 14 cases of diffuse alveolar hemorrhage syndrome].

  Yasuo Kohashi, Yuji Saito, Yoshitaka Totani, Yukiko Yoneda, Masamichi Hayashi, Mitsushi Okazawa, Hiroki Sakakibara
  [show abstract] [hide abstract]
  ABSTRACT: Diffuse pulmonary alveolar hemorrhage (DAH) is caused by various disorders and is a medical emergency that often results in acute respiratory failure requiring prompt diagnosis and aggressive treatment. However, the relationships between the prognosis and the initial clinical feature in DAH remain unclear. We investigated the relationships between initial clinical features and prognosis in 14 cases of DAH. We examined 14 patients with DAH about laboratory data, CT scan findings, treatment and outcome. Three of 14 patients died of acute respiratory failure due to DAH. In the laboratory data on admission, the patients with over 230 IU/L of serum LDH levels had a poor outcome. In pulmonary function data on admission, the patients with under 300 of P/F ratio had poor outcome. On CT scan findings on admission, the patients with consolidation shadows had a poor outcome compared to the patients with ground-glass shadows. In our data, serum LDH concentration, P/F ratio and CT scan findings on admission are important factors in the prognosis of DAH.
  Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society. 05/2009; 47(4):265-70.
• Article: [A case of advanced small cell lung cancer complicated by chronic renal failure treated with amrubicin].

  Sumito Isogai, Yoshitaka Totani, Yasuo Kohashi, Yuuki Mieno, Hiromi Imizu, Yukiko Yoneda, Hideyasu Shimizu, Tami Hoshino, Yasuhiro Uchiyama, Yasuo Takeuchi, Masamichi Hayashi, Yuji Saitoh, Fumihiko Sasaki, Mitsushi Okazawa, Hiroki Sakakibara
  [show abstract] [hide abstract]
  ABSTRACT: A 64-year old man first visited our clinic approximately 10 years ago because of diabetic nephropathy that had developed into chronic renal failure. He was hospitalized to examine a left S10 tumor shadow. Based on the results of these examinations, a primary left S10 T2N0M1, ED small cell lung cancer, was diagnosed. During his outpatient visits nephropathy was found. Following admission, he began dialysis (HD). During the detailed examinations, chemotherapy with amrubicin (AMR)was performed and the blood concentration of the drug was measured. The results showed no significant variations in blood concentration before and after the dialysis. While PR was achieved in this patient, a reduction in grade 4 eosinophils was observed as an adverse reaction.
  Gan to kagaku ryoho. Cancer & chemotherapy 10/2008; 35(9):1591-3.